Clinical Trials
15 trialsNCT04534205 2026-05-22
AHEAD-MERIT
BioNTech SE
Phase 2/3 Recruiting
NCT04442022 2026-05-06
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2/3 Active not recruiting
NCT03315364 2026-04-01
OPTIMAL
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3 Active not recruiting
NCT02598661 2026-01-05
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation
Phase 2/3 Active not recruiting
NCT06908772 2025-04-03
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
NCT06719479 2024-12-05
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
SUNHO(China)BioPharmaceutical CO., Ltd.
Phase 2/3 Not yet recruiting
NCT04155424 2024-09-25
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.
Phase 2/3 Terminated
NCT01518517 2022-02-02
GRASPIVOTALL
ERYtech Pharma
Phase 2/3 Completed
NCT02910063 2021-01-13
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Amgen
Phase 2/3 Completed
NCT01774578 2020-05-28
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2/3 Terminated
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT01197560 2019-11-25
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Celgene
Phase 2/3 Completed
NCT02186301 2019-05-07
EGFR
Clovis Oncology, Inc.
Phase 2/3 Terminated
NCT01639638 2015-03-12
Recurrent and Nonrecurrent Condyloma Treatment
Laboratorio Elea Phoenix S.A.
Phase 2/3 Terminated
NCT00165633 2008-12-09
A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
Eisai Inc.
Phase 2/3 Terminated